Prophylaxis Against Renal Transplant Rejection clinical trials

Explore recruiting prophylaxis against renal transplant rejection clinical trials.

Also recruiting in Europe

Prophylaxis Against Renal Transplant Rejection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients

Belgium, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A non-inferiority, randomised and controlled trial to compare the safety, tolerability and preliminary efficacy between standard and Torque Teno virus-guided immunosuppression in stable adult kidney transplant recipients with low immunological risk in the first year after transplantation

Netherlands, Czechia, France, Austria, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-daily tacrolimus formulations, Envarsus® compared with Advagraf™, administered in kidney transplant recipients

Germany

Therapeutic use (Phase IV) EU CTIS Study details

A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients

Sweden, Spain, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Long-Term Follow-Up of Patients Who Have Received An Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR-Treg therapy, TX200-TR101) In A Prior Clinical study

Belgium, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted from a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-Term Follow Up

Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

Prophylaxis Against Renal Transplant Rejection trials by city

Prophylaxis Against Renal Transplant Rejection in Toronto Prophylaxis Against Renal Transplant Rejection in Vancouver Prophylaxis Against Renal Transplant Rejection in Montreal Prophylaxis Against Renal Transplant Rejection in Calgary Prophylaxis Against Renal Transplant Rejection in Edmonton Prophylaxis Against Renal Transplant Rejection in Ottawa Prophylaxis Against Renal Transplant Rejection in Winnipeg Prophylaxis Against Renal Transplant Rejection in Quebec City Prophylaxis Against Renal Transplant Rejection in Hamilton Prophylaxis Against Renal Transplant Rejection in Kitchener Prophylaxis Against Renal Transplant Rejection in London Prophylaxis Against Renal Transplant Rejection in Halifax Prophylaxis Against Renal Transplant Rejection in New York Prophylaxis Against Renal Transplant Rejection in Los Angeles Prophylaxis Against Renal Transplant Rejection in Chicago Prophylaxis Against Renal Transplant Rejection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease